Interaction between genes and environment in neurodegenerative diseases

Comptes Rendus - Biologies

Volumn 330, Issue 4, 2007, Pages 318-328

  Elbaz, Alexis ^a   Dufouil, Carole ^a   Alpérovitch, Annick ^a  

^a INSERM   (France)

Author keywords

Alzheimer disease; Environment; Epidemiology; Gene; Parkinson disease

Indexed keywords

APOLIPOPROTEIN E; CYTOCHROME P450 2D6; INDUCIBLE NITRIC OXIDE SYNTHASE; PESTICIDE; XENOBIOTIC AGENT;

ENVIRONMENTAL FACTOR; EPIDEMIOLOGY; GENE; NERVOUS SYSTEM DISORDER; NEUROLOGY; POLYMORPHISM;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; ENZYME POLYMORPHISM; GENE IDENTIFICATION; GENETIC RISK; HEREDITY; HUMAN; NERVE DEGENERATION; PARKINSON DISEASE; PREVALENCE; PROTEIN POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SMOKING; XENOBIOTIC METABOLISM;

ALZHEIMER DISEASE; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEURODEGENERATIVE DISEASES; PARKINSONIAN DISORDERS; SMOKING;

EID: 34248146514     PISSN: 16310691     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crvi.2007.02.018     Document Type: Short Survey

References (78)

1. Murray C.J.L., and Lopez A.D. The Global Burden of Disease (1996), World Health Organisation, Geneva
2. Menken M., Munsat T.L., and Toole J.F. The global burden of disease study: implications for neurology. Arch. Neurol. 57 (2000) 418-420
3. Golbe L.I. Neurodegeneration in the age of molecular biology. BMJ 324 (2002) 1467-1468
4. Ioannidis J.P., Trikalinos T.A., and Khoury M.J. Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am. J. Epidemiol. 164 (2006) 609-614
5. Wong M.Y., Day N.E., Luan J.A., Chan K.P., and Wareham N.J. The detection of gene-environment interaction for continuous traits: should we deal with measurement error by bigger studies or better measurement?. Int. J. Epidemiol. 32 (2003) 51-57
6. Garcia-Closas M., Thompson W.D., and Robins J.M. Differential misclassification and the assessment of gene-environment interactions in case-control studies. Am. J. Epidemiol. 147 (1998) 426-433
7. Schatzkin A., and Slud E. Competing risks bias arising from an omitted risk factor. Am. J. Epidemiol. 129 (1989) 850-856
8. Slud E., and Byar D. How dependent causes of death can make risk factors appear protective. Biometrics 44 (1988) 265-269
9. Elbaz A., and Alperovitch A. Bias in association studies resulting from gene-environment interactions and competing risks. Am. J. Epidemiol. 155 (2002) 265-273
10. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., and Van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. J. Am. Med. Assoc. 278 (1997) 1349-1356
11. Rocca W.A., McDonnell S.K., Strain K.J., Bower J.H., Ahlskog J.E., Elbaz A., Schaid D.J., and Maraganore D.M. Familial aggregation of Parkinson's disease: The Mayo Clinic family study. Ann. Neurol. 56 (2004) 495-502
12. Twelves D., Perkins K.S.M., and Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov. Disord. 18 (2003) 19-31
13. Elbaz A., Bower J.H., Maraganore D.M., McDonnell S.K., Peterson B.J., Ahlskog J.E., Schaid D.J., and Rocca W.A. Risk tables for parkinsonism and Parkinson's disease. J. Clin. Epidemiol. 55 (2002) 25-31
14. de Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baldereschi M., Fratiglioni L., Lobo A., Martinez-Lage J., Trenkwalder C., and Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 (2000) S21-S23
15. Martinez-Martin P. An introduction to the concept of 'quality of life in Parkinson's disease'. J. Neurol. 245 (1998) S2-S6
16. Parashos S.A., Maraganore D.M., O'Brien P.C., and Rocca W.A. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin. Proc. 77 (2002) 918-925
17. Elbaz A., Bower J.H., Peterson B.J., Maraganore D., McDonnell S.K., Ahlskog J.E., Schaid D.J., and Rocca W.A. Survival study of Parkinson Disease in Olmsted County, Minnesota. Arch. Neurol. 60 (2003) 91-96
18. Checkoway H., and Nelson L.M. Epidemiologic approaches to the study of Parkinson's disease etiology. Epidemiology 10 (1999) 327-336
19. Elbaz A., McDonnell S.K., Maraganore D.M., Strain K.J., Schaid D.J., Bower J.H., Ahlskog J.E., and Rocca W.A. Validity of family history data on PD: Evidence for a family information bias. Neurology 61 (2003) 11-17
20. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7 (2006) 306-318
21. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., and Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607
22. Ozelius L.J., Senthil G., Saunders-Pullman R., Ohmann E., Deligtisch A., Tagliati M., Hunt A.L., Klein C., Henick B., Hailpern S.M., Lipton R.B., Soto-Valencia J., Risch N., and Bressman S.B. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354 (2006) 424-425
23. Hernan M.A., Takkouche B., CaamanoIsorna F., and GestalOtero J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 52 (2002) 276-284
24. Ross G.W., and Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drug Aging 18 (2001) 797-806
25. Galanaud J.P., Elbaz A., Clavel J., Vidal J.-S., Corrèze J.-R., Alpérovitch A., and Tzourio C. Cigarette smoking and Parkinson's disease: a case-control study in a population characterized by a high prevalence of pesticide exposure. Mov. Disord. 20 (2005) 181-189
26. Chen H., Zhang S.M., Schwarzschild M.A., Hernan M.A., and Ascherio A. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Mov. Disord. 21 (2006) 1002-1007
27. Menza M.A., Golbe L.I., Cody R.A., and Forman N.E. Dopamine-related personality traits in Parkinson's disease. Neurology 43 (1993) 505-508
28. Ishihara L., and Brayne C. What is the evidence for a premorbid parkinsonian personality: A systematic review. Mov. Disord. 21 (2006) 1066-1072
29. Wirdefeldt K., Gatz M., Pawitan Y., and Pedersen N.L. Risk and protective factors for Parkinson's disease: a study in Swedish twins. Ann. Neurol. 57 (2005) 27-33
30. Tanner C.M., Goldman S.M., Aston D.A., Ottman R., Ellenberg J., Mayeux R., and Langston J.W. Smoking and Parkinson's disease in twins. Neurology 58 (2002) 581-588
31. Hantraye P., Brouillet E., Ferrante R., Palfi S., Dolan R., Matthews R.T., and Beal M.F. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. 2 (1996) 1017-1021
32. Hunot S., Boissiere F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., and Hirsch E.C. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72 (1996) 355-363
33. Levecque C., Elbaz A., Clavel J., Richard F., Vidal J.-S., Amouyel P., Tzourio C., Alperovitch A., and Chartier-Harlin M.-C. Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. Hum. Mol. Genet. 12 (2003) 79-86
34. Hague S., Peuralinna T., Eerola J., Hellstrom O., Tienari P.J., and Singleton A.B. Confirmation of the protective effect of iNOS in an independent cohort of Parkinson disease. Neurology 62 (2004) 635-636
35. Hancock D.B., Martin E.R., Fujiwara K., Stacy M.A., Scott B.L., Stajich J.M., Jewett R., Li Y.J., Hauser M.A., Vance J.M., and Scott W.K. NOS2A and the modulating effect of cigarette smoking in Parkinson's disease. Ann. Neurol. 60 (2006) 366-373
36. Pogun S., Demirgoren S., Taskiran D., Kanit L., Yilmaz O., Koylu E.O., Balkan B., and London E.D. Nicotine modulates nitric oxide in rat brain. Eur. Neuropsychopharmacol. 10 (2000) 463-472
37. Mazzio E.A., Kolta M.G., Reams R.R., and Soliman K.F. Inhibitory effects of cigarette smoke on glial inducible nitric oxide synthase and lack of protective properties against oxidative neurotoxins in vitro. Neurotoxicology 26 (2005) 49-62
38. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
39. Priyadarshi A., Khuder S.A., Schaub E.A., and Shrivastava S. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 21 (2000) 435-440
40. Priyadarshi A., Khuder S.A., Schaub E.A., and Priyadarshi S.S. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ. Res. 86 (2001) 122-127
41. Liou H.H., Tsai M.C., Chen C.J., Jeng J.S., Chang Y.C., Chen S.Y., and Chen R.C. Environmental risk factors and Parkinson's disease: A case-control study in Taiwan. Neurology 48 (1997) 1583-1588
42. Seidler A., Hellenbrand W., Robra B.P., Vieregge P., Nischan P., Joerg J., Oertel W.H., Ulm G., and Schneider E. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 46 (1996) 1275-1284
43. Brown T.P., Rumsby P.C., Capleton A.C., Rushton L., and Levy L.S. Pesticides and Parkinson's disease - is there a link?. Environ. Health Perspect. 114 (2006) 156-164
44. Ascherio A., Chen H., Weisskopf M.G., O'Reilly E.J., McCullough M.L., Calle E.E., Schwarzschild M.A., and Thun M.J. Pesticide exposure and Parkinson's disease. Ann. Neurol. 60 (2006) 197-203
45. Baldi I., Lebailly P., Mohammed-Brahim B., Letenneur L., Dartigues J.-F., and Brochard P. Neurodegenerative diseases and exposure to pesticides in the elderly. Am. J. Epidemiol. 157 (2003) 409-414
46. Elbaz A., Levecque C., Clavel J., Vidal J.-S., Richard F., Amouyel P., Alpérovitch A., Chartier-Harlin M.C., and Tzourio C. CYP2D6 polymorphism, pesticides exposure, and Parkinson's disease. Ann. Neurol. 55 (2004) 430-434
47. Stewart W.F., and Stewart P.A. Occupational case-control studies: I. Collecting information on work histories and work-related exposures. Am. J. Ind. Med. 26 (1994) 297-312
48. LeCouteur D.G., McLean A.J., Taylor M.C., Woodham B.L., and Board P.G. Pesticides and Parkinson's disease. Biomed. Pharmacother. 53 (1999) 122-130
49. McCann S.J., Pond S.M., James K.M., and LeCouteur D.G. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J. Neurol. Sci. 153 (1997) 50-53
50. Deng Y., Newman B., Dunne M.P., Silburn P.A., and Mellick G.D. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. Ann. Neurol. 55 (2004) 897
51. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., and Hendrikse N.H. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 57 (2005) 176-179
52. Tan E.K., Chan D.K., Ng P.W., Woo J., Teo Y.Y., Tang K., Wong L.P., Chong S.S., Tan C., Shen H., Zhao Y., and Lee C.G. Effect of MDR1 haplotype on risk of Parkinson disease. Arch. Neurol. 62 (2005) 460-464
53. Furuno T., Landi M.T., Ceroni M., Caporaso N., Bernucci I., Nappi G., Martignoni E., Schaeffeler E., Eichelbaum M., Schwab M., and Zanger U.M. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12 (2002) 529-534
54. Drozdzik M., Bialecka M., Mysliwiec K., Honczarenko K., Stankiewicz J., and Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13 (2003) 259-263
55. Elbaz A., Dutheil F., Alpérovitch A., Loriot M.-A., and Tzourio C. Case-control study of the MDR1 gene in Parkinson disease. Mov. Disord. 21 15 (2006) S405 (suppl.)
56. Kelada S.N., Checkoway H., Kardia S.L., Carlson C.S., Costa-Mallen P., Eaton D.L., Firestone J., Powers K.M., Swanson P.D., Franklin G.M., Longstreth Jr. W.T., Weller T.S., Afsharinejad Z., and Costa L.G. 5′ and 3′ region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study. Hum. Mol. Genet. 15 (2006) 3055-3062
57. Richardson J.R., Caudle W.M., Wang M., Dean E.D., Pennell K.D., and Miller G.W. Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease. FASEB J. 20 (2006) 1695-1697
58. Caudle W.M., Richardson J.R., Wang M., and Miller G.W. Perinatal heptachlor exposure increases expression of presynaptic dopaminergic markers in mouse striatum. Neurotoxicology 26 (2005) 721-728
59. Ritchie K., and Lovestone S. The dementias. Lancet 360 (2002) 1759-1766
60. Mayeux R. Genetic epidemiology of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20 (2006) S58-S62
61. Mayeux R., Sano M., Chen J., Tatemichi T., and Stern Y. Risk of dementia in first-degree relatives of patients with Alzheimer's disease and related disorders. Arch. Neurol. 48 (1991) 269-273
62. Dufouil C., Tzourio C., Brayne C., Berr C., Amouyel P., and Alperovitch A. Influence of apolipoprotein E genotype on the risk of cognitive deterioration in moderate drinkers and smokers. Epidemiology 11 (2000) 280-284
63. Haan M.N., Shemanski L., Jagust W.J., Manolio T.A., and Kuller L. The role of APOE epsilon 4 in modulating effects of other risk factors for cognitive decline in elderly persons. J. Am. Med. Assoc. 282 (1999) 40-46
64. Zhu L., Fratiglioni L., Guo Z.C., Basun H., Corder E.H., Winblad B., and Viitanen M. Incidence of dementia in relation to stroke and the apolipoprotein E epsilon 4 allele in the very old - Findings from a population-based longitudinal study. Stroke 31 (2000) 53-60
65. Yaffe K., Haan M., Byers A., Tangen C., and Kuller L. Estrogen use, APOE, and cognitive decline - Evidence of gene-environment interaction. Neurology 54 (2000) 1949-1953
66. Peila R., White L.R., Petrovich H., Masaki K., Ross G.W., Havlik R.J., and Launer L.J. Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment - The Honolulu-Asia aging study. Stroke 32 (2001) 2882-2887
67. Ruitenberg A., vanSwieten J.C., Witteman J.C.M., Mehta K.M., vanDuijn C.M., Hofman A., and Breteler M.M.B. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 359 (2002) 281-286
68. Peila R., Rodriguez B.L., and Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies - The Honolulu-Asia Aging Study. Diabetes 51 (2002) 1256-1262
69. Hofman A., Ott A., Breteler M.M.B., Bots M.L., Slooter A.J.C., vanHarskamp F., vanDuijn C.M., VanBroeckhoven C., and Grobbee D.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349 (1997) 151-154
70. Podewils L.J., Guallar E., Kuller L.H., Fried L.P., Lopez O.L., Carlson M., and Lyketsos C.G. Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am. J. Epidemiol. 161 (2005) 639-651
71. Jarvik G.P., Wijsman E., Kukull W.A., Schellenberg G.D., Yu C., and Larson E.B. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45 (1995) 1092-1096
72. Dufouil C., Richard F., Fievet N., Dartigues J.F., Ritchie K., Tzourio C., Amouyel P., and Alperovitch A. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study. Neurology 64 (2005) 1531-1538
73. Chandra V., and Pandav R. Gene-environment interaction in Alzheimer's disease: A potential role for cholesterol. Neuroepidemiology 17 (1998) 225-232
74. Kivipelto M., Helkala E.L., Laakso M.P., Hanninen T., Hallikainen M., Alhainen K., Iivonen S., Mannermaa A., Tuomilehto J., Nissinen A., and Soininen H. Apolipoprotein E epsilon 4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 137 (2002) 149-155
75. Hall K., Murrell J., Ogunniyi A., Deeg M., Baiyewu O., Gao S., Gureje O., Dickens J., Evans R., Smith-Gamble V., Unverzagt F.W., Shen J., and Hendrie H. Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology 66 (2006) 223-227
76. Evans R.M., Emsley C.L., Gao S., Sahota A., Hall K.S., Farlow M.R., and Hendrie H. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: A population-based study of African Americans. Neurology 54 (2000) 240-242
77. Maraganore D.M., De Andrade M., Elbaz A., Farrer M.J., Ioannidis J.P., Kruger R., Rocca W.A., Schneider N., Lesnick T.G., Lincoln S.J., Hulihan M.M., Aasly J.O., Ashizawa T., Chartier-Harlin M.C., Checkoway H., Ferrarese C., Hadjigeorgiou G., Hattori N., Kawakami H., Lambert J.C., Lynch T., Mellick G.D., Papapetropoulos S., Parsian A., Quattrone A., Riess O., Tan E.K., and van Broeckhoven C. Collaborative analysis of the alpha-synuclein gene promoter variability and Parkinson's disease. J. Am. Med. Assoc. 296 (2006) 661-670
78. Elbaz A., Nelson L.M., Payami H., Ioannidis J.P., Fiske B.K., Annesi G., Carmine-Belin A., Factor S.A., Ferrarese C., Hadjigeorgiou G., Higgins D.S., Kawakami H., Kruger R., Marder K.S., Mayeux R.P., Mellick G.D., Nutt J.D., Ritz B., Samii A., Tanner C.M., van Broeckhoven C., Van Den Eeden S.K., Wirdefeldt K., Zabetian C.P., Dehem M., Montimurro J.S., Southwick A., Myers R.M., and Trikalinos T.A. Lack of replication of thirteen single nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol. 5 (2006) 917-923